[go: up one dir, main page]

WO2002100263A1 - Dispositifs analytiques dont le capteur est loge dans le trocart - Google Patents

Dispositifs analytiques dont le capteur est loge dans le trocart Download PDF

Info

Publication number
WO2002100263A1
WO2002100263A1 PCT/GB2002/002632 GB0202632W WO02100263A1 WO 2002100263 A1 WO2002100263 A1 WO 2002100263A1 GB 0202632 W GB0202632 W GB 0202632W WO 02100263 A1 WO02100263 A1 WO 02100263A1
Authority
WO
WIPO (PCT)
Prior art keywords
electrode
fluid
trocar
electrode device
retraction
Prior art date
Application number
PCT/GB2002/002632
Other languages
English (en)
Inventor
Neil Buckley
Andrew Gill
Daniel Rose
Suzy Stone
Maximilian Bielenberg
Graham Michael Pullin
Paul Stephen South
Original Assignee
Iit Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iit Limited filed Critical Iit Limited
Publication of WO2002100263A1 publication Critical patent/WO2002100263A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6848—Needles
    • A61B5/6849—Needles in combination with a needle set
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3468—Trocars; Puncturing needles for implanting or removing devices, e.g. prostheses, implants, seeds, wires

Definitions

  • PCT/GB93/00163 discloses a method of installing an electrode in place in vivo which comprises the step of providing at the site of insertion a protecting medium which, without injuring the biological environment, suppresses the adverse depressive effect of the electrode's output induced by the biological environment.
  • the protecting medium is then modified or replaced by an aqueous surrounding medium which allows the electrode to become exposed to the surrounding environment, and so allowing the measurement of analytes from the environment.
  • the present invention relates to devices, kits and methods for determining the presence or concentration of one or more analytes present in a patient, and more especially to providing microflow electrode devices which can be used by patients and physicians.
  • the present invention further relates to providing disposable electrode devices.
  • the present invention is particularly concerned with devices for determining of blood glucose levels to assist in the management of diabetes.
  • the devices, kits and methods described below employ the microflow conditions disclosed in PCT/GB00/03253, that is where a flow of liquid is supplied to the sensing surface of the electrode which is sufficient to keep undesirable contaminants or fouling components away from the electrode surface, while still allowing the desired analyte to diffuse towards the electrode and thus be determined.
  • the flow of fluid to the tissue or other medium under examination should be in a quantity low enough to avoid any unacceptable degree of dilution of the tissue or media being monitored at a rate such that the fluid can mingle with the tissue or media and form a zone in which the rate of diffusion at which the analyte can reach the sensing surface of the electrode is greater than the rate of flow of the microflow fluid outwards from the surface.
  • the present invention concerns an. electrode device which enables an electrode to be inserted at a site in a patient's body, e.g. in the interstitial space between the skin and vascularised tissue below, and in a way that is acceptable to the patient and which does not damage the electrode.
  • the benefits of this trocar retraction mechanism are (i) that it ensures the sensor tip is delivered reproducibly and accurately to the interstitial tissue to the desired projection beyond the end of the microflow cannula to benefit from the protective microflow effect, (ii) that it prevents accidental damage to the sensor tip upon insertion, since no positive force is required to place the sensor beyond the cannula and (iii) that it keeps the sharp within the body of the device thus avoiding sharp disposal.
  • the trocar retraction mechanism comprises a retraction arm attached to the body of the device which is moveable to cause retraction of the trocar.
  • the body portion of the electrode device is provided with a base plate for seating the device against the patient and the retraction arm is pivotally attached to the body of the device.
  • the retraction arm is moveable from a first position in which the trocar is extended to a second position in which the trocar is retracted and retraction arm is approximately coplanar with the base plate. This arrangement helps to stabilise the electrode device when it is in place on the patient, assisted by providing the base plate, and optionally the retraction arm, with adhesive pad(s).
  • the present invention further provides a locking mechanism to prevent premature retraction of the trocar prior to insertion into the medium/patient. If this happened, then the electrode would become exposed, risking damage to the electrode and especially its sensing surface, and damage to the patient, if an attempt was made to insert the exposed electrode into tissue.
  • the locking mechanism can take the form of a locking pin which fixes the retraction arm in place until the locking pin is removed.
  • protective membranes are disclosed in PCT/GB00/02665 (compositions comprising an impermeable polymer and a polyvinylpyridine) and WO99/10520 (polyurethane modified by surfactant) .
  • Preferred electrodes of the invention have sensing surface which include immobilised enzyme, e.g. immobilised on the surface of the electrode or in one or more fenestrations along its sensing surface (e.g. see PCT/GB00/0305 ) .
  • any of the metals in the form of the element or a compound used for the study of electrochemically active species (a) any of the metals in the form of the element or a compound used for the study of electrochemically active species (ascorbate, paracetamol etc) , membrane covered electrodes using such metals and membranes of materials such as ion-exchange polymers or materials of controlled porosity.
  • materials such as polyether sulphones (PES), polyvinyl chlorides (PVC) and products such as Nafion; these can be used in conjunction with neurotransmitters such as dopamine and noradrenalin.
  • oxygen electrodes which are similar to enzyme electrodes but can be operated at higher voltages, e.g. approximately +0.6V against a silver/silver chloride electrode (Ag/AgCl) reference electrode.
  • Microflow fluid preferably Ringer's solution, possibly including isotonic saline, isotonic saline including 5mM potassium or phosphate buffered saline, is initially perfused actively across the sensor tip under an initial priming force applied by the fluid retaining pouch.
  • This priming force is to (i) expel any air from the device prior to insertion (ii) to initially hydrate the interstitial tissue around the sensor which allows rapid equilibration of the sensor within the tissue, allowing reliable glucose measurements to be made within 30 min of sensor installation.
  • the negative interstitial tissue pressure naturally draws microflow fluid at a rate typically in the range 30-60 ⁇ l/h.
  • the electrode device preferably also includes fluid delivery device for supplying fluid to the cannula, e.g. so that a microflow of fluid can be established over the sensing surface of the electrode in use.
  • the fluid delivery device may comprise a tube linked to an external supply of fluid or the fluid may be supplied from a reservoir inside the body portion of the device.
  • the device includes in the flow path " from the fluid delivery device to the cannula, a chamber or length of tubing between the fluid connection and the cannula through which fluid is supplied.
  • This has the advantage of helping the fluid supplied through the cannula to equilibrate to body temperature prior to infusion into the patient. This assists patient compliance and also helps to minimise errors that may be caused by differences in the temperature of the microflow fluid.
  • the fluid delivery device primes the electrode device by expelling air from the fluid connector and the electrode assembly, and supplies an initial volume of fluid around the sensing surface of the electrode which has the advantage of reducing the time before measurements can be made. After the initial higher flow rate of fluid, the device then supplies a lower flow rate (e.g. at a microflow rate), assisted by a slight negative tissue pressure where the electrode is implanted into a patient.
  • a lower flow rate e.g. at a microflow rate
  • the priming procedure can be facilitated by providing a fluid pathway between the trocar tip and the cannula through which air or microflow fluid can be expelled on priming.
  • the fluid pathway may be provided by provdmg the trocar tip with a flattened region (as shown in Figure 10) , an aperture or other formation to provide the necessary route for the expulsion of air or fluid.
  • fluid is supplied to the electrode device via the tube from a separate fluid supply bag.
  • the fluid supply bag can be housed in a casing and comprises a port for connection to the tube.
  • one of the port and the end of the tube can be provided with a self sealing membrane and the other with a spike, allowing the two to be joined together in an airtight and sterile manner.
  • Alternative constructions such as male and female connectors will be apparent to the skilled person.
  • the fluid supplied to the electrode can in addition to providing the microflow semi-permeable layer over the sensing surface of the electrode can include one or more ingredient required for the reactions taking place at the electrode or to improve the performance of the electrode or device.
  • these ingredients can include anti-coagulants for inhibiting coagulation on the electrode surface, such as heparin, hirudine, prostaglandin, a carboxylated amine such as EDTA; substances for modifying the viscosity of the fluid; an analgesic; one or more components of a buffering system; isotonicising agents; anti-inflammatory agents; preservatives; sterilising agents; agents to render tissues more permeable to liquids or electrolytes; or antibiotics.
  • the present invention provides an electrode device and a fluid delivery device as described herein .
  • the analyte determinations made using the electrode device are used to control the administration of a pharmacologically active agent to a patient.
  • the present invention provides an electrode device as described herein in combination with a drug delivery device, the drug delivery device comprising a controller for receiving analyte concentration data from the electrode device and a drug reservoir for providing doses of drug to the patient operable under instructions from the controller.
  • the present invention allows continuous real time monitoring of an analyte concentration and consequent dosing with the drug in response to the concentration of the analyte.
  • This aspect of the invention is particularly suited to the treatment of diabetes with insulin or an anti-diabetic drug, controlling the administration of the drug by determining glucose concentrations (e.g. measurements made interstitially) , as it reduces the fluctuations in glucose and insulin levels that result from conventional intermittent measurement and treatment.
  • glucose concentrations e.g. measurements made interstitially
  • the present invention provides a method of determining an analyte in vivo in a patient, the method comprising: connecting the electrode device to a fluid supply device, the devices being as described above; priming the electrode device by introducing fluid from the fluid delivery device to flush air from the electrode device; locating an electrode device on the patient and inserting the electrode assembly; retracting the trocar using the trocar retraction mechanism to expose the electrode; supplying fluid through the cannula to flow over the electrode surface; and, making one or more measurements of analyte concentration using the device
  • the method may involve the optional step of securing the device in place using an adhesive pad present on the device or an adhesive pad placed over it.
  • the method may involve the further step of dosing the patient with a drug in response to the determination of analyte concentration.
  • Figure 1 shows an external, perspective view of the electrode device ready to use with the locking pin removed.
  • Figure 2 shows an external, perspective view of the electrode device with the locking pin in place.
  • Figures 3 and 4 show internal views of the electrode device, in particular showing the support for the electrode assembly and the trocar retraction mechanism.
  • Figure 5 shows representation of the locking pin.
  • Figure 8 shows a housing for the fluid supply bag.
  • Figure 9 shows a fluid connector for linking the fluid supply bag to the electrode assembly.
  • Figure 10 shows a preferred form of fenestrated trocar that is designed to allow flow of microflow fluid through the trocar.
  • the present invention relates to a device which facilitates the insertion of an electrode into a patient for making in vivo measurements of analytes, e.g. to determine blood glucose levels to assist in the management of diabetes.
  • the electrode device 2 comprises a body portion 4, a base plate 6, a retraction arm 8 pivotally attached to the body portion 4 so that it is capable of moving from a first position in which it is approximately perpendicular to the base plate 6 (shown in Figures 1 and 2) to a second position, in which the retraction arm 8 and base plate 6 are approximately coplanar.
  • the device is provided with a locking pin 10 which prevents movement of the retraction arm 8 before the device is employed.
  • the construction of the locking pin 10 is shown in detail in Figure 5.
  • the locking pin 10 acts upon the trocar retraction arm 8, blocking the movement of the arm in a forwards direction that would otherwise result in the retraction of the trocar 16 into the body of the device under the action of the trocar retraction cord moving over the moulded arc 40.
  • the locking pin 10 blocks movement of 36 by impeding action of 8 on the rounded end of 36 (see Figure 3) .
  • FIGS 1 and 2 also show electrical 24 and fluid 26 connectors linking the electrode device to an external display for taking measurements using the implanted electrode and as means for supplying fluid to the electrode assembly 12, described in more detail below.
  • the electrode assembly 12 comprises a cannula 14, containing within it a trocar 16 having a sharp end 18 to enable the electrode assembly to be inserted into a patient.
  • the electrode itself is held within the cannula and trocar and is disposed so that the sensing end of the electrode extends beyond the end of the cannula 14, i.e. so that cannula, trocar and electrode are arranged in a concentric manner.
  • the electrode is positioned relative to the trocar 16 so that it is held within the trocar 16 in its extended position shown in Figure 1 and 2, but extends beyond the end of the trocar when the trocar is in its retracted position.
  • the end of the electrode assembly can be provided with a removable protective cap (not shown) to cover the sharp trocar prior to use.
  • FIGS 3 and 4 show perspective views of the device in which a housing part of the body portion 4 and retraction arm 8 are removed to show the trocar retraction mechanism inside the device.
  • the electrode assembly is fixed to the base plate 6 via supporting collar 28.
  • the collar 28 supports the electrode assembly 12 at the correct angle for insertion (about 30 degrees) and ensures that the end of the trocar 16 extends beyond the plane of the base plate 6 to allow insertion of the electrode at the correct depth into the relevant tissue.
  • the supporting collar 28 is fixedly joined to arms 30 having inwardly facing teeth 32 which form part of a ratchet mechanism with a second set of teeth 34 provided on retractor cord 36.
  • the electrode is preferably arranged so that it extends beyond the end of the cannula.
  • the inventors found that this improved the presentation of the sensor tip to the tissue in which the measurements are made.
  • the locking pin 10 is useful as it prevents a careless user of the device from prematurely withdrawing the trocar prior to insertion into the patient, causing damage to the electrode and pain to the patient.
  • the construction of the electrode forms another aspect of the invention.
  • the electrode 42 is shown in Figure 6 and comprises a platinum or platinum iridium core 44 surrounded by a stainless steel sheath 46.
  • the electrode is inserted inside the cannula and trocar as described above and is linked via electrical connector 24 to a conventional control and display device.
  • the electrode has a sensing tip 48 which can be formed in any of a number of geometries suitable for sensing analytes.
  • the end of the electrode is provided with immobilised enzyme, e.g. glucose oxidase for determining glucose levels in a patient's tissue.
  • the electrode may be coated with one or more membranes as described above.
  • the electrode is a platinum-iridium electrode.
  • Figure 10 shows a preferred form of trocar 16 having fenestrations 17 that are designed to allow flow of microflow fluid through the trocar so that during priming, air is completely removed from the device, and then during operation, microflow fluid continues to percolate through the cannula 14 and trocar 16 so avoiding any stagnant pools of fluid within the device which could lead to undesirable changes in sensor output that result from leaching of substances from the stagnant areas to the sensor tip.
  • the present invention concerns the construction of the electrode and the supply of fluid to the sensing tip of the electrode, especially to achieve the microflow conditions as described in our earlier application PCT/GB00/03253.
  • the elements of the fluid delivery system are shown in Figures 7 to 9.
  • a fluid bag 50 typically formed from a flexible plastic material is provided with a port 52 having a tear off cap 54, the port 52 being sealed by a membrane 56.
  • the fluid bag is about 50 x 80mm in size and holds enough microflow fluid for priming and supplying an electrode device 2 for 24 hours.
  • the fluid bag 50 is adapted to fit inside casing 60.
  • the casing 60 is formed from rigid plastic and comprises two matching halves 62, hinged together and designed to snap in the closed position around the fluid bag 50, with the port of the bag protruding through aperture 64.
  • the casing 60 is further provided with internal ridges 66, or alternatively a spring formation, to provide a controlled amount of pressure to the fluid bag 50, to pump an initial volume of fluid from the bag for priming the electrode device, principally to flush air from the device before the electrode assembly is inserted into a patient, and to help to control the pressure of the fluid supplied to the electrode after priming to provide fluid to the electrode under microflow conditions.
  • Apertures 68 are provided in the casing to allow it to be carried with a patient, e.g. attaching the casing with a safety pin though the apertures to the patient's clothes.
  • Figure 9 shows an example of a connector 70 that can be linked to the end of the fluid connector 26.
  • This allows the fluid connector 26 to be linked to the fluid delivery system by removing the tear off cap 54 from the fluid bag inside the casing 60 and pushing the connector 70 through membrane 56 which then seals around the connector 70 providing a robust and sterile seal.
  • pressure from the casing pumps fluid through the electrical connector 26 and into the cannula 14 of the electrode assembly 12, flushing air from the fluid delivery system and the electrode device 2.
  • the device 2 can then be installed in the patient and the trocar 16 withdrawn to expose the electrode for making measurements of analyte concentration.
  • the fluid delivery system continues to pump fluid from the fluid bag 50 to hydrate the insertion site so that the electrode can rapidly equilibrate with its surrounding and establish a baseline signal.
  • the fluid delivery system is designed to reduce the flow of fluid, relying on light pressure from the casing and the inherent negative pressure of the patient's body to provide fluid through the cannula to the vicinity of the electrode.
  • the electrode assembly 12 is connected via fluid connector 26 to a fluid reservoir 60 which supplies fluid down the space between the electrode and the cannula.
  • the fluid is supplied under microflow conditions as described in PCT/GB00/03253, i.e. to form a permeable liquid layer of the fluid around the sensing tip of the electrode and maintained over the electrode and interposed between the medium under examination and the active surface of the electrode.
  • the rate of flow of the fluid is controlled so that it allows analyte to pass through permeable liquid layer to the sensing tip by diffusion, while resricting the flow of contaminants from the surrounding medium which can foul the electrode leading to a reduction in its useful working life and/or errors in measurements .
  • the slight negative pressure of the body of the patient can be employed to help to draw the fluid from the reservoir into the patient's body via the cannula.
  • the fluid reservoir shown in Figure 6 is adapted to prime the device ready for use to remove air from the fluid connector and the cannula to minimise the risk of introducing air into the patient when the device is employed.
  • the fluid reservoir is also designed to pump an initial dose of the microflow fluid to the insertion site around the electrode's sensing tip as this has the advantage of reducing the lag time before measurements can be made by rapidly hydrating the site with the microflow fluid. This active priming of the device rapidly establishes a baseline electrode response and provides a hydrated environment around the insertion site which enables electrochemical determinations of analyte concentration to be made.
  • the device is adapted to allow the fluid introduced at the electrode insertion site to equilibrate towards body temperature before exiting the device at the subcutaneously implanted cannula. This is achieved by running the fluid connector 26 adjacent the base plate 6 of the device 2 so that it is proximal to the patient's body.
  • the equilibration of the temperature of the fluid also has the advantage of improving the performance of the electrode sensor.
  • the initial hydration of the implant site initiates glucose diffusion from the cellular compartment to the interstitial space in which the sensing tip of the electrode is located. This allows the measurement of glucose levels to begin more rapidly than would otherwise be possible, without the priming effect of the microflow fluid.
  • further microflow fluid is drawn to the site by the body's inherent negative tissue pressure, providing a slow flow of fluid across the sensor tip, typically at rates in the order of 30-60 ⁇ l/hour, serving to continue hydration of the insertion site and improving the diffusion of glucose to the sensor tip.
  • the slow flow of microflow fluid also continues to prevent fouling of the sensitive sensor tip through deposition of protein and colloid material from the medium under investigation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

L'invention concerne des dispositifs, des ensembles et des procédés faisant intervenir une électrode destinée à être insérée dans un patient. Selon l'invention, un flux de liquide est alimenté à la surface de détection de l'électrode de manière à éloigner des contaminants parasites ou des salissures, tout en permettant à l'analyte visé de diffuser vers l'électrode et ainsi d'être déterminé. L'invention concerne notamment un dispositif permettant d'insérer correctement l'électrode sur un site du corps du patient, par ex. dans l'espace interstitiel entre la peau et les tissus vascularisés sous-jacents, d'une manière acceptable pour le patient et n'endommageant pas l'électrode. L'invention concerne par ailleurs un système d'amorçage et de distribution de fluide destiné à alimenter un microflux fluidique à l'électrode insérée.
PCT/GB2002/002632 2001-06-12 2002-06-12 Dispositifs analytiques dont le capteur est loge dans le trocart WO2002100263A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0114290A GB0114290D0 (en) 2001-06-12 2001-06-12 Analytical devices kits and methods of use
GB0114290.0 2001-06-12

Publications (1)

Publication Number Publication Date
WO2002100263A1 true WO2002100263A1 (fr) 2002-12-19

Family

ID=9916418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002632 WO2002100263A1 (fr) 2001-06-12 2002-06-12 Dispositifs analytiques dont le capteur est loge dans le trocart

Country Status (2)

Country Link
GB (1) GB0114290D0 (fr)
WO (1) WO2002100263A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658876A1 (fr) * 2004-11-17 2006-05-24 Clinico GmbH Dispositif d'extraction pour extraire de façon protégée une aiguille flexible à ponction d'un cathéter
EP1863559A2 (fr) * 2005-03-21 2007-12-12 Abbott Diabetes Care, Inc. Procede et systeme permettant d'obtenir un systeme de controle de substance a analyser et de perfusion de medicament integre
US9064107B2 (en) 2006-10-31 2015-06-23 Abbott Diabetes Care Inc. Infusion devices and methods
US9750440B2 (en) 2005-05-17 2017-09-05 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US10872102B2 (en) 2009-07-23 2020-12-22 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954643A (en) * 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954643A (en) * 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658876A1 (fr) * 2004-11-17 2006-05-24 Clinico GmbH Dispositif d'extraction pour extraire de façon protégée une aiguille flexible à ponction d'un cathéter
US7220242B2 (en) 2004-11-17 2007-05-22 Clinico Gmbh Withdrawal device for the secure withdrawal of a flexible puncture needle from a catheter, in particular from a catheter with a flexible catheter tube
EP1863559A2 (fr) * 2005-03-21 2007-12-12 Abbott Diabetes Care, Inc. Procede et systeme permettant d'obtenir un systeme de controle de substance a analyser et de perfusion de medicament integre
EP1863559A4 (fr) * 2005-03-21 2008-07-30 Abbott Diabetes Care Inc Procede et systeme permettant d'obtenir un systeme de controle de substance a analyser et de perfusion de medicament integre
US10206611B2 (en) 2005-05-17 2019-02-19 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US9750440B2 (en) 2005-05-17 2017-09-05 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US10007759B2 (en) 2006-10-31 2018-06-26 Abbott Diabetes Care Inc. Infusion devices and methods
US9064107B2 (en) 2006-10-31 2015-06-23 Abbott Diabetes Care Inc. Infusion devices and methods
US11043300B2 (en) 2006-10-31 2021-06-22 Abbott Diabetes Care Inc. Infusion devices and methods
US11508476B2 (en) 2006-10-31 2022-11-22 Abbott Diabetes Care, Inc. Infusion devices and methods
US11837358B2 (en) 2006-10-31 2023-12-05 Abbott Diabetes Care Inc. Infusion devices and methods
US12073941B2 (en) 2006-10-31 2024-08-27 Abbott Diabetes Care Inc. Infusion device and methods
US10872102B2 (en) 2009-07-23 2020-12-22 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels

Also Published As

Publication number Publication date
GB0114290D0 (en) 2001-08-01

Similar Documents

Publication Publication Date Title
US20240033429A1 (en) Integrated analyte sensor and infusion device and methods therefo
US9028409B2 (en) Fluid delivery with in vivo electrochemical analyte sensing
JP3993210B2 (ja) アナライトの検出および治療用物質の管理のための装置
US6254586B1 (en) Method and kit for supplying a fluid to a subcutaneous placement site
CN100391400C (zh) 一种用来检测分析物含量的介入最小的系统和方法
EP2339958B1 (fr) Appareils capteurs d'analyte ayant des configurations d'électrodes améliorées, et leurs procédés de fabrication et d'utilisation
US5951521A (en) Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
EP0320109A1 (fr) Système de mesure
US9265455B2 (en) Methods and systems for optimizing sensor function by the application of voltage
US20120277667A1 (en) Analyte monitoring and fluid dispensing system
US20100268043A1 (en) Device and Method for Preventing Diabetic Complications
JP2011507556A5 (fr)
EP2732837A2 (fr) Ensemble de capteur et de perfusion combiné utilisant des sites séparés
CA2787010A1 (fr) Ensembles de capteur et dispositif de perfusion combines
US20200222630A1 (en) Methods and devices for fluid delivery and analyte sensing via an implantable port
WO2002100263A1 (fr) Dispositifs analytiques dont le capteur est loge dans le trocart

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP